MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
3 reports, 2 independent
Updated Sep 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Alvotech announces development of biosimilar to Humira.1 source
MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.1 source
Keep exploring
The entities involved
-
Alvotech
biotechnology company
-
MarketBeat
American personal finance blog
-
HUMIRA
Czech company
Nothing else this week.
Related events
- MarketBeat provided analyst ratings for Editas Medicine and Alvotech, both of which are listed on the Nasdaq stock exchange.
- MarketBeat provides analyst recommendations and compares FAT Brands and Centerra Gold as materials companies.
- MarketBeat provided analyst recommendations and compared Organon & Co. and Xeris Biopharma.
- MarketBeat provided analyst ratings and compared MSC Industrial Direct and Mitsui & Co. as industrial investment options.
- Eton Pharmaceuticals and Biofrontera, small-cap healthcare companies, are noted for their revenue and earnings, with MarketBeat providing analyst ratings.